glofitamab-gxbm (Columvi)

Indications

• diffuse large B-cell lymphoma*

* improves overall survival over rituximab

Dosage

• pretreatment with 1 g intravenous obinutuzumab 7 days priot to the 1st dose of glofitamab
• cycle 1: day 8: 2.5 mg glofitamab IV; day 15: 10 mg IV
• cycle 2-12: 30 mg on day 1
• cycles lasted 21 days

* 1 mg/mL

Adverse effects

• >= grade 3: 62%
  • cytokine release syndrome
  • gastrointestinal hemorrhage
  • neutropenia
  • sepsis
  • delirium

• drug adverse effects of pharmaceutical monoclonal antibodies

Mechanism of action

• CD20-CD3 bispecific monoclonal antiboduy
  • 2:1 tumor:T-cell binding configuration
    • bivalent for CD20 (B-cells) & monovalent for CD3 (T-cells)

More general terms

• antineoplastic monoclonal antibody